Patents by Inventor Andrew J. Garman

Andrew J. Garman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7060446
    Abstract: Assay device which is able to detect molecules which inhibit the binding of a ligand to a receptor using extremely small quantities of ligand and receptor sample. Such devices are useful in the discovery of molecules which may modulate the activity of biologically important target molecules. The device comprises a microfabricated diffusion chamber into which is introduced in mixture of a test compound, a receptor and a ligand for the receptor. Test compounds which can prevent binding of the ligand to the receptor are identified by detecting the presence of ligand outside the area of introduction of the mixture in the diffusion chamber.
    Type: Grant
    Filed: October 11, 1999
    Date of Patent: June 13, 2006
    Assignee: AstraZeneca AB
    Inventor: Andrew J Garman
  • Patent number: 6846668
    Abstract: The microfabricated cell injector having an injection wall and a cell injection needle projecting from the wall for piercing cells suspended in a fluid. The needle is held within a housing defined by the internal surfaces of the microfabricated cell injector. The housing has an inlet for suspended cells to enter and an outlet for cells to exit via the cell injection needle. A cell propulsion device is provided for impelling cells towards the needle such that, in use, cells suspended in the fluid are impelled towards the injection wall by the injection needle.
    Type: Grant
    Filed: October 7, 1999
    Date of Patent: January 25, 2005
    Assignee: AstraZeneca AB
    Inventors: Andrew J. Garman, David J. Scanlon, John Dodgson, John Ea Shaw, David Brennan, Anthony R. Corless, Christopher M. Turner
  • Patent number: 5552535
    Abstract: A method for the synthesis of a plurality of oligonucleotides comprising the steps of(i) forming a first oligonucleotide on a first cleavable link attached to a solid support;(ii) attaching to the first oligonucleotide a cleavable linker moiety;(iii) forming a second oligonucleotide on the cleavable linker moiety; and(iv) cleaving the first cleavable link and the cleavable linker moiety to give a plurality of oligonucleotides; wherein the cleavable linker moiety is of the Formula (1): ##STR1## in which A.sup.1, A.sup.2 and E are as defined herein, and novel compounds which may be used in the operation of the method.
    Type: Grant
    Filed: November 7, 1994
    Date of Patent: September 3, 1996
    Assignee: Zeneca Limited
    Inventors: Michael J. McLean, David Holland, Andrew J. Garman, Robert C. Sheppard
  • Patent number: 5441867
    Abstract: Pre-activated stable protein reagents are provided. The reagents can be made by reaction of the protein and a heterobifunctional linker and have extended stability especially after lyophilisation. The reagents can be used in assay kits to form conjugates with proteins e.g. antibodies or polynucleotides e.g. oligonucleotides probes.
    Type: Grant
    Filed: January 7, 1992
    Date of Patent: August 15, 1995
    Assignee: Zeneca Limited
    Inventors: Andrew J. Garman, John R. Parker
  • Patent number: 5393877
    Abstract: A method for the synthesis of a plurality of oligonucleotides comprising the steps of(i) forming a first oligonucleotide on a first cleavable link attached to a solid support;(ii) attaching to the first oligonucleotide a cleavable linker moiety;(iii) forming a second oligonucleotide on the cleavable linker moiety; and(iv) cleaving the first cleavable link and the cleavable linker moiety to give a plurality of oligonucleotides; wherein the cleavable linker moiety is of the Formula (1): ##STR1## in which A.sup.1, A.sup.2 and E are as defined herein, and novel compounds which may be used in the operation of the method.
    Type: Grant
    Filed: April 5, 1993
    Date of Patent: February 28, 1995
    Assignee: Zeneca Limited
    Inventors: Michael J. McLean, David Holland, Andrew J. Garman, Robert C. Sheppard
  • Patent number: 4935465
    Abstract: A conjugate comprising a pharmaceutically useful protein linked to at least one water-soluble polymer by means of a reversible linking group.
    Type: Grant
    Filed: November 27, 1985
    Date of Patent: June 19, 1990
    Assignee: Beecham Group p.l.c.
    Inventor: Andrew J. Garman
  • Patent number: 4673573
    Abstract: A fibrinolytically active protein conjugate comprising at least one optionally blocked fibrinolytic enzyme linked by way of a site other than the catalytic site responsible for fibrinolytic activity to at least one human protein.Processes from making the conjugates and pharmaceutical compositions containing them are also described.
    Type: Grant
    Filed: January 9, 1985
    Date of Patent: June 16, 1987
    Assignee: Beecham Group p.l.c.
    Inventors: Harry Ferres, Richard A. G. Smith, Andrew J. Garman
  • Patent number: 4609547
    Abstract: Pharmaceutical compositions are described for anti-allergy therapy comprising an allergen or allergen extract, polysarcosine having an average molecular weight in the range of 2,000 to 12,000 and a chemical linking group connecting a reactive site on the polysarcosine to an amino group on the allergen or allergen extract, the reactive site on the polysarcosine being a H(CH.sub.3)N--, the allergen extract being an extract from an allergen selected from pollens, weeds, house dust mites and venoms, and the chemical linking group having the formula --CO--B--CO where B is a hydrocarbon chain of 1-4 carbon atoms. The disclosure also describes the analogous conjugates.
    Type: Grant
    Filed: April 26, 1984
    Date of Patent: September 2, 1986
    Assignee: Beecham Group p.l.c.
    Inventors: Andrew J. Garman, Alan Wheeler